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Abstract:  Owing to the increasing importance of aquaculture to compensate for the 
progressive worldwide reduction of natural fish and to the fact that several fish farming 
plants often suffer from heavy financial losses due to the development of infections caused 
by microbial pathogens, including multidrug resistant bacteria, more environmentally-
friendly strategies to control fish infections are urgently needed to make the aquaculture 
industry more sustainable. The aim of this review is to briefly present the typical fish 
farming diseases and their threats and discuss the present state of chemotherapy to 
inactivate microorganisms in fish farming plants as well as to examine the new 
environmentally friendly approaches to control fish infection namely phage therapy and 
photodynamic antimicrobial therapy. 
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1. Introduction  
 
Aquaculture comprises all types of culture of aquatic animals and plants in fresh, brackish and 
marine environments [1]. Aquaculture has many forms, being the most frequent open net pens or cages 
in offshore areas and ponds and tanks in coastal or inland waters. Offshore aquaculture is often used to 
raise salmon and trout. Inland aquaculture is used to raise a variety of finfish such as catfish, 
yellowtail, tilapia and seabream. Offshore pens, cages and coastal ponds being open to the surrounding 
water means that the fish can potentially be infected with and/or transmit waterborne diseases to/from 
wild stocks. Fully enclosed or recirculating systems farming has the advantage of being land based and 
not having to be in close proximity to the sea. 
Aquaculture provides nearly one-third of the world’s seafood supplies and is one of the fastest 
growing agricultural sector. Over the past ten years, aquaculture production has increased on average 
by 6% per year [2]. Production has increased from 8.7 million tons of fish in 1990 to 31.6 million tons 
in 2006 [2,3]. Fish farming plants, however, often suffer from heavy financial losses [4-6], due to the 
development of infections caused by microbial pathogens, including multidrug resistant bacteria that 
are easily transmitted through water and therefore able to infect a great variety of fish species.  
 
1.1. Fish Farming Diseases 
 
Cultured fishes are constantly threatened by microbial attacks. The main biological agents that 
cause water-borne diseases are bacteria, viruses, protists and helminths, oomycetes and, to a lesser 
extent, fungi. However, bacterial diseases are main problems in the expanding aquaculture   
industry [7-9]. Several fish farming plants often suffer from heavy losses owing to the frequent 
development of infections caused essentially by bacteria. There are two broad groups of bacteria of 
public health significance that contaminate fish: those naturally present in the environment-the 
indigenous microflora (e.g., Photobacterium damselae, Vibrio  anguillarum, V. vulnificus, Aeromonas 
hydrophila, Aeromonas. salmonicida ) and those introduced through environmental contamination by 
domestic animals excreta and/or human wastes – non-indigenous microflora (e.g., Enterobactereaceae 
such as Salmonella sp. and Escherichia coli) [10-16]. Although there is a rapid die-off of enteric 
bacteria in managed farm fish, significant numbers of those bacteria remain on the skin and in the guts 
of fish and can cause a health risk to consumers. Vibriosis and photobacteriosis (formerly 
pasteurellosis) are primarily diseases of marine and estuarine fish, both in natural and commercial 
production systems throughout the world, occurring only occasionally in freshwater fish. Vibriosis and 
photobacteriosis diseases can cause significant mortality in fish, reaching values of up to 100% in 
infected facilities, being currently responsible for the most outbreaks of fish farming plants. The 
vibriosis and photobacteriosis are caused by bacteria from the family Vibrionaceae. Vibriosis is caused 
by species from the genera Photobacterium (namely Photobacterium damselae  subsp. damselae, 
formerly  Vibrio damselae ) and Vibrio (namely V. anguillarum ,  V. v ulnificus,  V. alfinolyticus ,  
V. parahaemolyticus and V. salmonicida). Photobacteriosis is caused by P. damselae subsp. piscicida 
(formerly Pasteurella piscicida) that is a highly pathogenic bacterium that does not seem to have host 
specificity, infecting potentially an ample range of fish species [17,18]. Starting from 1990, European Mar. Drugs 2009, 7                         
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countries (especially Southern European countries) were confronted with this pathogen. Since then, 
several countries from the Mediterranean area such as France, Italy, Spain, Greece, Portugal, Turkey, 
Malta, Israel and Croatia, have been dealing with high mortality rates in cultured populations of 
seabass (Dicentrarchus labrax) and seabream (Sparus aurata) [19]. At the present, photobacteriosis 
continues to be a severe problem in intensive culture of different fish species in the Mediterranean area 
and Japan. Vibrionaceae species are also known to cause disease in humans, most often following to 
the consumption of contaminated aquaculture products. Rickettsia-like bacteria are also an important 
group of fish pathogens, affecting a variety of fish species from diverse geographical aquatic 
environments [20]. A. salmonicida, causative agent of furunculosis, is also a fish pathogen that is 
capable of infecting a wide range of host species [21]. Edwardsiella tarda  causes mortalities of 
flounder [22,23]. A gliding bacteria Cytophaga marina (formerly Flexibacter maritimus) that produces 
extracellular toxins has been occurring in red and black sea breams, yellowtail and in flounder [24,25]. 
Flexibacter sp. had occurred also in sea urchin hatcheries [26]. Flavobacterium psychrophilum and 
more recently Pseudomonas plecoglossicida  have been recognized as important pathogens of 
freshwater fish [27]. 
Viral diseases can cause heavy losses in production in marine aquaculture industry [6,28]. Although 
human infections caused by the consumption of fish appear to show a low risk because viruses causing 
disease in fish are not pathogenic to humans, many different viruses are known pathogens of already 
well-studied fishes, such as yellowtail [29], Japanese flounder [30,31] and black seabream [32]. Other 
viruses are still being discovered [33], such as spot syndrome viruses that now constitute a new virus 
family [34]. Viruses infecting commercial fish have been intensively studied and have found to 
encompass a wide range of viral families, including Irodovirus, Rhabdovirus, Birnavirus, Nodavirus, 
Reovirus, and Herpesviruses [35,36]. Some of these viruses have broad host ranges and seem to 
circulate between marine waters and freshwaters, making the transmission of the virus to new areas a 
serious threat. Two rhabdoviruses that cause infectious haematopoietic necrosis in salmonids of North 
America and haemorrhagic septicaemia in trout of Europe farms have been detected in other continents 
and have been also isolated in a broad range of other fish species [37-39]. 
Parasite-related food safety concerns in aquaculture are limited to a few helminth species, and the 
hazards are largely focused on communities where consumption of raw or inadequately cooked fish is 
a cultural habit [40]. The main human diseases caused by fish-borne parasites are trematodiasis, 
cestodiasis and nematodiasis. There is a lack of specific and quantitative information about the extent 
of the hazard in fish but the little information available indicates that trematode parasites are 
transmitted from farmed fish [40]. Parasites are also a concern because they often cause damage to fish 
tissue, creating an ideal location for bacterium infection to begin. 
Infections caused by aquatic Oomycetes can affect eggs, fingerlings and adult fishes when they get 
injured mechanically or as a result of infections by other microorganisms. Such fish infections are 
common in freshwater and brackish water throughout the world [41,42] and are considered the second 
cause of infection, after bacteria, in freshwater aquaculture. Oomycetes infections caused by members 
of Saprolegnia represent a major challenge to a number of freshwater fishes [43,44]. Saprolegnia has a 
large impact on salmonids [45,46] but infects also a number of other fishes [47]. Saprolegnia 
infections in aquaculture were kept under control with malachite green, but this chemical has been Mar. Drugs 2009, 7                         
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banned worldwide since 2002 due to its carcinogenic and toxicological effects. Consequently, 
Saprolegnia parasitica  is now, in economic terms, a very important fish pathogen, especially for 
catfish, salmon and trout species. Aphanomyces invadans is also an invasive oomycete pathogen of 
freshwater and estuarine fishes [48] that is the main aetiological agent of epizootic ulcerative 
syndrome, infecting many species of fish. Phoma herbarum has been associated with outbreaks of 
systemic mycosis in salmonid fish [49,50].  
Diseases are more frequent in farmed fish than in the wild. Farmed fish live at greater density than 
wild fish which enhances the transference of pathogens between individuals. Overfeeding, high 
temperature and fast growth to cultivate fish as soon as possible in fish farming plants create 
unfavorable conditions. Moreover, overfeeding causes accumulation of organic wastes which are feed 
for microorganisms increasing the risk of disease outbreaks. Sick, moribund and dead fish increase 
also the risk of pathogens when they are not properly removed from the farming area, namely if water 
renewal rate is low. Also, opportunistic pathogens may become more aggressive in a polluted 
environment. It has been shown that pathogenic microorganisms are not introduced to the aquatic 
environment by farmed fish [51] but it has been suggested that wild fish are the major source of 
pathogens [51]. The frequency of sick individuals in wild stocks is usually low, but the number of 
infected individuals can be high because fish can be infected without being diseased. The wild infected 
fish can run rampant in densely packed offshore and inland aquaculture fish farms [51]. Records of 
offshore and inland aquaculture of fish indicate the prevalence of the same species of bacteria and 
viruses [35,52-55]. However, the parasite pathogenic communities of aquaculture cultured fish 
appeared to vary with changes in salinity and with a decline in fish richness and diversity [56]. Some 
species like salmon and trout, that are farmed mainly in offshore area, develop a specific pathogenic 
infectious salmon anaemia virus [57-59]. This virus causes an emerging infection in Atlantic Salmon 
at the time when the most prevalent bacteria infections were gradually brought under control [58]. The 
salmon anaemia virus was first detected in 1984 in Norwegian farms, appeared in Canada in 1996 and 
reached the Scottish salmon farms in 1998. Virus appeared in Clilean farms in 1999, in Farol Island 
and USA in 2001. The main reservoir for salmon anaemia virus is marine environment and the 
dominant transmission route is horizontal transmission [59]. Vertical transmission of salmon anaemia 
virus represents a new route of transmission within farmed populations of salmonids [60]. There is no 
evidence sufficient to link farmed fish to disease outbreaks in wild pacific salmon but evidence 
suggests that wild fish are the major sources of salmon anaemia virus [61]. Salmon and trout farms act 
also as a reservoir for sea lice, a parasite that is easily spread from one fish to another [62,63]. 
 
1.2. Preventive Measures in Fish Farming Plants 
 
Disease prevention is the preferred health management and most cost-effective option with respect 
to aquaculture diseases. However, it is not always economically feasible to culture the animals under 
optimal conditions and give them the optimal feed, so the risk of infection and the need of effective 
biocontrol techniques always exist. Prevention and control of infections are especially difficult in fish 
farming conditions, due to the ubiquitous nature and the rapid spreading of such pathogens. The 
problem is further accentuated by several factors, such as (1) low microbiological water quality (high Mar. Drugs 2009, 7                         
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levels of faecal indicators of water quality) in many fish farms [16,64,65] (2) irregular and adverse 
environmental conditions (e.g., increased temperatures, salinity changes, oxygen depletion, high 
organic loads) which can act as predisposing agents for the outbreak of the disease, often by 
weakening the innate defense systems of the fish [54]; (3) high stocking densities (higher than that 
indicated by each species) used in fish farming plants decreases resistance to infection [54];   
(4) different stages of the fish life cycle are susceptible to infections [66]; (5) increasing problems with 
resistance against antibiotics in common pathogenic bacteria and the concern about spreading of 
antibiotics in the environment [54]; (6) many chemotherapeutic agents that are effective against 
bacteria and oomycetes exhibit a low activity against endospores and zoospores [66]; (7) significant 
number of pathogenic spores persist on the fish epidermis even after quarantine [66]; and (8) few drugs 
are licensed for fisheries use [31,35,67]. 
 
1.2.1. Vaccination 
 
Although vaccination would be the ideal method for the prevention of infectious diseases, 
commercially available vaccines in the aquaculture field are still very limited [68-71]. Pasteurelosis 
and vibriosis have been controlled to a great extent through the use of vaccines [68,72]. A toxoid-
enriched whole-cell vaccine against Photobacterium damsela piscicida was applied by bath immersion 
achieving 75% survival when applied to fish with 0.5-2.0 g. A vaccine against the Vibrio spp. has 
proven effective in European Salmonid aquaculture, especially when administered by injection. 
Prophylactic immunization for other bacterial diseases of farmed fish has been attempted with some 
success, namely against Aeromonas salmonicida and Yersinia ruckeri [72]. Vaccinated fishes appear to 
grow and survive better than their unvaccinated counterparts, however the exact nature of the 
immunity provided is not clear [71]. Currently, injectable polyvalent vaccines are used because some 
fish are vulnerable to infections by multiple bacterial strains. However, there are still no commercially 
available vaccines against two other important bacterial fish diseases: bacterial kidney disease and 
rickettsial septicaemia. Moreover, vaccination is not possible in the case of fish larvae, which 
generally are most susceptible to disease, because it is practically unfeasible to handle these small 
animals and also because it is believed that fish larvae do not have the ability to develop specific 
immunity [73].  
The development of vaccines for fish viral diseases was rather unsuccessful for a long period. There 
were developed killed virus vaccines for two viral diseases, infectious pancreatic necrosis virus and 
infectious hematopoietic necrosis virus, and a recombinant DNA based vaccine for infectious 
pancreatic necrosis virus [74]. However, only the recombinant DNA produced vaccine is commercially 
available. The killed virus vaccines have produced unsatisfactory results due to killed virus residual 
virulence in the target species, virulence for other fish species, persistence in the treated fish and the 
fear that the virus might revert to virulence [75,76]. As happens with bacteria, the difficulty in 
developing anti-viral vaccines is due to the fact that these diseases occur primarily at the fish fry age 
and it is difficult to inject these small animals. 
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1.2.2. Chemotherapy  
 
Although chemotherapy has shown to be a rapid and effective method to treat or prevent infections, 
the more frequently used chemotherapeutic agents are often responsible for the development of drug 
resistant microbial strains. The regular use of artificial feeds supplemented with antibiotics in intensive 
and semi-intensive aquaculture systems to prevent the spread of disease and their massive use to 
control infections has resulted in the development of resistant strains, which have made antibiotic 
treatments ineffective. As microorganisms replicate rapidly, the possibility of a mutation quickly 
becomes predominant throughout the microbial population, which helps a microbe to survive, for 
instance, in the presence of an antibiotic drug. In fact, in marine environment more than 90% of 
bacterial strains are resistant to more than one antibiotic and 20% are resistant to five at   
least [77]. The horizontal transfer of resistance to human pathogens and the presence of antibiotic and 
of other drugs residues in aquaculture products for human consumption constitute important threats to 
public health, generating problems of allergy and toxicity and probably carrying out alterations of the 
normal human gut microflora [78]. Antibiotic-resistant microorganisms also enter into the marine 
water environment from human and animal sources. These bacteria are able to spread their genes in 
water-indigenous bacteria, which also contain resistance genes, increasing the problems associated 
with antibiotic resistant bacteria in the environment, namely in fish farming plants [79]. 
Approximately half of the world’s antibiotics are used for animals [80], as in fish farms, where 
antibiotics are used as growth promoters. In Asiatic countries where aquaculture is an important 
industry, a great variety of antibiotics, equivalent to 500-600 tones per year, are used in a prophylactic 
way, some on a daily basis [81]. In Thailand, 56 of the 76 farmers considered in the study of 
Holmstrom et al. used antibiotics [82]. More than ten different antibiotics, including chloramphenicol, 
gentamycin, trimethoprim, tiamulin, tetracyclines, quinolones and sulfonamids were used. Tendencia 
and Pena reported the use of a great variety of antibiotics in the Phillipines, including oxytetracycline, 
oxolinic acid chloramphenicol, furozolidine, nitrofurans, erythromycin and sulfonamids [83]. In South 
America, a broad range of antibiotics is also used in aquaculture, namely oxytetracycline, florfenicol, 
trimethoprim-sulfamethoxazole, sarafloxacin and enrofloxacin [84]. In Europe, chemotherapy is also 
widely practiced in aquaculture, but only a limited number of legislated antibiotics are allowed, such 
as amoxacillin, ampicillin, chloramphenicol, erythromycin, florfenicol, flumequine, oxolinic acid, 
oxytetracycline, nitrofurazone, sulphadiazine-trimethoprim and tetracycline [18,67,85,86]. The 
emergence of antibiotic resistant pathogens obligates the ban or restriction on the use of antibiotics by 
various producing (exporting) and consuming (importing) countries. This situation reflects the need for 
the development of alternative technologies to antibiotics in aquaculture to control bacterial pathogens. 
Other biocides than antibiotics are also extensively used in the worldwide aquaculture industry to 
treat protozoal and fungal infections. The most frequently used are malachite green and formaldehyde. 
Malachite green is a triarylmethane dye that is highly effective against important protozoal and fungal 
infections [87-89]. Basically, it works as an ectoparasiticide, but it has also been used to control skin 
flukes and gill flukes. Although topically applied, these compounds might also be absorbed 
systemically and produce significant internal effects. Today it is well known that malachite green is 
environmentally persistent and produces a wide range of acute toxic effects on various fish species and Mar. Drugs 2009, 7                         
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certain mammals [90]. It causes serious public health hazards and also poses potential environmental 
problems. Consequently, malachite green has become in a highly controversial compound due to the 
risks it poses to the consumers of treated fish [91] including its effects on the immune, respiratory and 
reproductive systems and its genotoxic, carcinogenic and mutagenic properties [90]. Despite the use of 
this dye has been banned in 2002 in several countries, it is still being used in many parts of the world 
due to its low cost, ready availability, efficacy and lack of a proper alternative. On the other hand, 
there is also concern about the fate of malachite green, as its reduced form, leucomalachite green, that 
occur as a contaminant in aquatic and terrestrial ecosystems [92] and, as mentioned, potential human 
health hazards. Moreover, some bacterial isolates from diseased carp and trouts have been found to be 
resistant to malachite green [93]. More recently, potential alternative chemicals to malachite green, 
like bronopol (2-bromo-2-nitropropane-1,3-diol), chlorine dioxide, hydrogen peroxide and humic 
acids, were explored. Bronopol it is being used for the treatment of fish and appears to be a safe and 
effective replacement for malachite green in prevention of fungal-like infections [94,95]. Chlorine 
dioxide [96] and hydrogen peroxide [97] have also been found to control fungal-like infections in fish 
as effectively as malachite green. Humic acids have also been evaluated as alternative   
disinfectants [98].  
Formaldehyde and formalin formulations are also used as disinfectants for prophylaxis of fish eggs 
and in first stages of larval development of fish [42,99]. Effects of sodium chloride, formalin and 
iodine on the hatching success of common carp eggs have been showed [99] and have been proposed 
as an effective treatment to reduce mortality in infected adult fish [42]. However, the use of 
formaldehyde has a significant environmental impact and is also suspected that to pose carcinogenic 
risk to mammals, causing harmful effects on human health [42]. Its use is therefore disencouraged, 
limited or even banned in several countries [100].  
In this way, to reduce the risk of development and spreading of microbial resistances and to control 
fish diseases in aquaculture, alternative strategies must be developed to allow the use of reasonably 
cheap and more environmentally friendly methods. In this revision, we present the state of 
chemotherapy to inactivate microorganisms in fish farming plants as well as the new environmentally 
friendly approaches to control fish infection.  
 
2. Phage Therapy: A Low Environmental Impact Technology as an Alternative to Antibiotics 
 
Bacterial diseases are a major problem in the expanding aquaculture [7-9]. The increasing problems 
related with worldwide emergence of antibiotic resistance in common pathogenic bacteria, such as 
vancomycin-resistant enterococci and multidrug resistant staphylococci, and concern about spreading 
of antibiotics in the environment due to anthropogenic activities, come out the need to find new 
methods to control fish bacterial pathogens. Phage therapy represents a potentially viable alternative to 
antibiotics and to other antibacterial compounds to inactivate indigenous and non-indigenous 
pathogenic bacteria in fish farming plants. 
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2.1. Bacteriophages in the Marine Environment 
 
Based on the new classification system proposed by Raoult and Forterre for viruses, a prokaryotic 
virus can be defined as a capsid-encoding organism that is composed by proteins and nucleic acids, 
self-assembles in a nucleocapsid that uses a ribosome-encoding prokaryotic organism for the 
completion of its life cycle [101]. 
The world of prokaryotic viruses, including the traditional bacteriophages (phages) and the viruses 
of Archaea, is currently in a period of renaissance, due to metagenomic sequencing advances and the 
isolation of diverse novel virus-host systems [102]. The resurgence of interest in prokaryotic viruses 
began in the mid 1990s as a consequence of the extraordinary abundance in the biosphere, especially 
in the marine environment, and of the unchallenged acceptance of the fact that viruses represent the 
greatest pool of genetic diversity on the planet [103-105]. Nowadays, phage research is as alive and 
full of promises as it was during its apogee of the 1960s and early 1970s [102]. Coincidentally, there 
was a parallel reawakening of interest in exploiting the enormous diversity of viruses that infect 
bacterial pathogens for phage therapy to control or prevent diseases from bacterial origins. 
Viruses are, by far, the most abundant biological entities in the aquatic systems [106-110]. Their 
enormous abundance (around 10
10-10
11 particles L
-1 of water) [36,111,112] and vast diversity still need 
more studies to provide the vital clues to the real function of viruses in natural ecosystems. The 
estimation of 10
30-31 viruses in marine waters [36,108,113] corresponds to 10
23-25 viral infections per 
second [36,114]. Most marine viruses are bacteriophages that kill bacteria [112], playing a significant 
role on the prokaryotic communities [36]. Viral lysis in surface waters removes 20-40% of the 
standing stocks of prokaryotes each day [115] and can match grazing by protists as a source of 
mortality of bacteria [111,112,116]. Consequently, viral lysis plays a significant role on the cycling of 
nutrients and organic matter [106]. In addition, viruses may influence the species composition of 
microbial communities [108]. They have a restricted range of host cells and, consequently, infection 
by a particular virus does not act on total microbial assemblage but rather on specific sub-populations.  
In the marine environment most phages have dsDNA genome [112], belonging mainly (96% of the 
total) to Caudoviridales order (families Myoviridae, Siphoviridae and Podoviridae) [117]. The first 
metagenomic analysis focused on phages/viruses confirmed the dominance of dsDNA tailed phages in 
marine viral communities [118-120], but also metagenomic approach showed that a large number of 
sequences (6% of the total) correspond to ssDNA phages belonging to Microviridae family [103]. This 
group was previously overlooked because the amplification and cloning excluded ssDNA viruses. 
RNA phages are also present in the marine environment [121-126] but in a recent metagenomic 
analysis of coastal waters no RNA phages were detected [104]. However, Culley et al. showed that the 
marine environment is a reservoir of previously unknown RNA viruses, revealing that 98% of RNA 
viruses belong to positive-sense ssRNA viruses [104] and that the predominant hosts of marine RNA 
viruses are eukaryotes. In that study, however, most of the RNA phages were classified as unknown 
and maybe some of them are RNA phages, since there are only a few number of viral RNA sequences 
in the databases, which difficults viral diversity interpretation. Other studies also showed that RNA 
viruses are an important component of the marine virome [127]. Mar. Drugs 2009, 7                         
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Most of the bacteriophages used in phage therapy in marine environment belong to the dsDNA 
groups, specifically to Siphoviridae family [12,27,128-130] and rarely to Myoviridae   
family [12,27,128]. However, high mutation rates and short generation times of RNA phages make 
them a dynamic population of genetic variants that are capable of infecting multiple host species [131], 
which suggests that RNA phages might be important agents for phage therapy. 
The study of virus-host interactions is essential in order to make possible use of bacteriophages to 
inactivate pathogenic bacteria in the aquatic environment. Viruses can interact with their hosts in two 
major and distinctive ways, the lytic and lysogenic cycles of infection and more sporadically through 
pseudolysogeny. In the lytic cycle the phages replicate their genome, producing new progeny viruses 
that are released through cell host lysis into the environment where they infect new bacterial cells. This 
capability to destroy bacteria is in the basis of using lytic phages as therapeutic or prophylactic agents. 
Phage multiplication is very rapid, they replicate exponentially as bacteria, declining when the number 
of bacteria decreases and disappearing when bacteria die. This behaviour contrasts with antibiotics 
where that decay, after application, occurs by excretion or by metabolic degradation.  
A lysogenic infection occurs when the viral genome is integrated into the nucleic acid of host cell 
and replicates together with it, passing onto daughter cells. Prophages remain dormant within the host 
chromosome until the lytic cycle is induced by physical or chemical agents, such as radiation, 
pollutants and changes in temperature, salinity and nutrient concentration [132-135]. The expression of 
lytic genes following damage to the host DNA by any of the above mechanisms is a viral strategy that 
has evolved to ensure viral propagation when conditions for host survival are compromised [136]. 
Lysogeny might be a viral survival strategy to ensure periods of low host density during nutrient 
starvation [137,138]. Lysogenic bacteria may also gain specific advantages from their relationship with 
phages that improve their overall fitness. These effects may occur through process of conversion, 
whereby prophage genes are expressed in the lysogens, resulting in expanded metabolic capabilities, 
antibiotic resistance and toxin production, but usually in homoimmunity [139] that provides resistance 
to superinfection by the same or similar strains of phages. There are some classical data referring that 
E. coli cells containing prophage grow up quicker than nonlysogenic E. coli strain [140,141]. 
Pseudolysogeny (i.e., false lysogen) is described as a phenomenon where there is a constant 
production of phage in the presence of high host cell abundance [142]. The phage lysis results not in 
total host death, some cells are not destroyed, but rather in a state whereby a high abundance of phage 
coexists with exponential host growth. This might be the result of a mixture of sensitive and resistant 
host cells and/or a mixture of temperate and virulent phages. In pseudolysogeny infection, 
bacteriophage can either proceed with lytic infection or enter a dormant intracellular phase [108] but in 
this case, the phage genome does not integrate into host cellular replicons. Pseudolysogeny is an 
environmental condition in which starved bacterial cells coexist in an unstable relationship with 
infective viruses [143,144]. Under these conditions, host cells do not provide enough energy in order 
to phage entering into a true lysogenic or lytic condition.  
The prevalence of lytic and lysogenic infection in the marine environment is a topic of considerable 
debate. Freifelder stated that more than 90% of known bacteriophages are temperate [138], but other 
authors [133,142,145] suggested that only around 50% of bacterial strains contained inducible Mar. Drugs 2009, 7                         
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prophages. Although a great percentage of phages are temperate, they are not suitable candidates for 
phage therapy since they may not immediately destroy bacteria.  
 
2.2. Phage Therapy and Its Clinical Applications 
 
Even though phages were discovered by the early 1920s and their infectious cycles understood by 
that time, the literature of the past half-century is almost silent on the possible therapeutic role of 
phages against infectious diseases. The poor understanding of mechanisms of bacterial pathogenesis 
and the nature of phage-host interactions, including lysogeny, led to a succession of badly designed 
and executed experiments. On the other hand, with the advent of antibiotic therapy, the use of phages 
became disregarded after the Second World War. In the 1970s, recovering previous enthusiasm on the 
application of phages to prevent and to treat human infections [146,147], studies of Smith et al. using 
E. coli models with mice and farm animals, showed that phages could be used for both treatment and 
prophylaxis against bacterial infections [148]. Thereafter, many other Polish and ex-Soviet Union 
study groups showed successful clinical usages of phages for drug-resistant infections in   
humans [146]. After this, many successful results using animal models were showed. The therapeutic 
efficacy of phage therapy against infectious diseases caused by Pseudomonas aeruginosa [149,150], 
Staphylococcus aureus  (including methicillin-resistant S. aureus ) [151,152], E. coli  [147], 
Enterococcus f aecium (including vancomycin-resistant  Enterococcus) [153], Streptococcus 
pneumoniae [154], Helicobacter pylori  [155], Klebsiella pneumoniae  [156] and Salmonella  
enteritidis [157,158] has been shown in experimental animal models. With regards to human health, in 
the past, phage was administered in Poland and the Soviet Union orally, tropically or systemically to 
treat a wide variety of infections (suppurative wound, gastroenteritis, sepsis, osteomyelitis, dermatitis, 
emphysemas and pneumonia) in both adults and children [146]. In general the success rates were of 
80-95% and neither adverse reactions nor reversible diseases were detectable. Consequently, in the 
Eastern Europe commercialization of phage therapy products was rapid. For instance, in the 1930s, Eli 
Lilly produced seven phage products for treat a range of infections, including abscesses, suppurating 
wounds and respiratory infections [159]. However, the evaluation of the efficacy of the phage therapy 
was based only on qualitative clinical assessment without details of doses and of other clinical   
criteria [146]. On the other hand, by 1940, the discovery of antibiotics diverted research attention from 
phage therapy, namely in the USA and Western Europe. However, the use of the phage therapy has 
persisted without interruption in Eastern Europe and phages are being commercialized by a number of 
companies [160]. The emergence of antibiotic-resistant bacteria has substancially enhanced the interest 
in phage therapy even by USA and Western Europe. Phage therapy is now ongoing phase I/II clinical 
trials and by 2011 it can reasonably be envisioned that phage treatments would be into phase III or in 
clinical use [102]. Nowadays, more than a dozen companies and universities are working on phage 
therapy for human, using current standards of clinical and microbiological research [161]. An 
Escherichia coli phase II trial is in preparation in order to control E. coli diarrhea by the Mestle 
Research Centre of Switzerland and no adverse reactions were detected. A successful phase II trial 
against antibiotic-resistant Pseudomonas aeruginosa ear infection was already completed in the UK by 
the BioControl Company. The company is now pursuing a phase III trial in the near future. Mar. Drugs 2009, 7                         
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2.3. Phage Therapy and Its Fish Farm Application 
 
Recent studies testify the use of bacteriophages as biocontrol agents in food [158,162-164], in 
plants [165], to control cyanobacterial blooms and for wastewater treatment [166]. Although phages of 
some fish-pathogenic bacteria have been described and characterized [151,167-173], these studies 
were mainly concerned with identifying bacteriophages for use in bacterial typing schemes or for the 
characterization of bacteriophages properties, including their potential role in virulence. However, 
there have been few attempts (Table 1) to use phages towards preventing bacterial infections in   
fish [15,27,174]. The results of these few studies using phages specific to Lactococcus garvieae and to 
P. plecoglossicida, pathogens of yellowtail and of ayu (Plecoglossus altivelis), respectively, suggest 
that phages could be useful for controlling bacterial infections of fish. 
 
Table 1. Use of bacteriophages to control pathogenic bacteria. 
Reference P hage  Bacteria  Treated 
fish/shellfish 
Phage application  Effects 
Barrow et 
al., 1998 
[147] 
Bacteriophage R 
isolated from 
domestic sewage 
E. coli H247 
(O18:K1:H7) 
(bacteremic) 
Chickens and 
calves 
Intramuscular (10
2-10
6 PFU) 
and intracranial (10
6 PFU) 
inoculation of chickens; oral 
and intramuscular inoculation 
of calves with 3 × 10
10 PFU) 
Protection 
against 
morbidity and 
mortality 
Biswas et 
al., 2002 
[153] 
 
Enterococcus phages 
ENB6 and C33 
isolated from raw 
sewage 
Vancomycin-
resistant 
Enterococcus 
faecium (agent 
of VRE 
bacteremia) 
BALB/c mice  Intraperitoneal injection of  
3 × 10
8 PFU 
Complete 
rescue of 
bacteraemia 
in 48 hours 
Bogovazova 
et al., 1991 
[156] 
Klebsiella 
pneumoniae 
bacteriophage 
Klebsiella  BALB/c mice  Intraperitoneal, intravenous 
or intranasal administration 
Rescue of 
generalized 
Klebsiella 
infection 
Cao et al., 
2000 
[155] 
Helicobacter pylori 
M13 recombinant 
phage 
Helicobacter 
pylori 
BALB/c mice  Oral administration of  
10
7 PFU 
Reduction of 
stomach 
colonization 
by 
Helicobacter 
pylori 
Fiorentin et 
al., 2005 
[157]  
Salmonella enteritidis 
lytic phages CNPSA 
1, CNPSA 3, CNPSA 
4 
Salmonella 
enteritidis 
Chicken cuts 
(thighs and 
drumsticks) 
Immersion in 10
9 CFU mL
-1 
bacteriophage suspensions  
Reduction of 
Salmonella 
enteritidis 
counts in 
treated 
chicken cuts  Mar. Drugs 2009, 7                         
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Table 1. Cont. 
Flaherty 
et al., 
2000 
[165]  
Xanthomonas campestris 
pv. vesicatoria specific H-
mutant bacteriophages 
Xanthomonas 
campestris pv. 
vesicatoria 
“Sunbeam” 
tomato 
Lycopersicon 
esculentum 
Foliar 
applications of 
10
8 PFU mL
-1 
phage suspensions 
Reduction of 
bacterial spots and 
increase in fruit 
weight 
Goode et 
al., 2003 
[163] 
 
Salmonella enteritidis phage 
types P125589, phage 29C 
and transducing lambdoid 
phage P22, HTint, isolated 
on S. enterica serovar 
Enteritidis from sewage; 
Campylobacter jejuni phage 
12673 
Salmonella 
enterica serovar 
Enteritidis and 
Campylobacter 
jejuni 
Chicken skin  Surface spreading 
with 10
3 PFU cm
-2  
Reduction by 2 log 
units in bacterial 
abundance over 48 
hours 
Hagens 
et al., 
2004 
[149] 
Genetically engineered non-
replicating, non-lytic 
filamentous phage Pf3R 
obtained from phage Pt1 
isolated from river water 
using PAO1 as the host 
Pseudomonas 
aeruginosa 
BALB/c mice  Intraperitoneal 
inoculation with  
10
6-10
8 PFU  
Higher survival 
rate and reduced 
inflammatory 
response after  
12-24 hours 
Huff et 
al., 2005 
[164] 
 
Escherichia coli phages 
SPR02 and DAF6 
Escherichia coli 
isolated from 
poultry  
Broiler 
chickens 
 
Injection in the air 
sac with 10
4 or  
10
8 PFU mL
-1 
phage suspensions 
and bird spraying 
with phage 
suspensions 
Decreased bird 
mortality 
Imbeault 
et al., 
2006 
[175]  
HER 110  Aeromonas 
salmonicida HER 
1107 
Brook trout 
Salvelinus 
fontinalis 
Addition to 
aquarium water of 
stock 
bacteriophage 
suspensions  
10
9 PFU mL
-1 
The onset of 
furunculosis in 
brook trout was 
delayed by 7 days 
Jado et 
al., 2003 
[154] 
Phage-coded lysins 
(enzybiotic): Pal amidase 
and/or Cpl-1 lysozyme 
Antibiotic-resistant 
Streptococcus 
pneumoniae 541, 
serotype 6B 
BALB/c mice  Intraperitoneal 
injection of 1 mg 
mL
-1 (110 000  
U mg
-1) enzyme 
solutions 
Rescue of 
bacteraemia and 
prevention of death 
in 72 hours 
Karunasa
gar et al., 
2007 
[130] 
Siphoviridae isolated from 
from oyster tissue and from 
shrimp hatchery water 
Vibrio harveyi  Shrimp larvae 
Penaeus 
monodon  
Ammendment of 
water in hatchery 
tanks with 
bacteriophage 
suspension  
(10
6 PFU mL
-1) 
Improved larval 
survival 
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Table 1. Cont. 
Leverentez 
et al., 2001 
[162] 
Salmonella – 
specific phages 
Salmonella 
enteritidis 
Fresh-cut fruit 
(melons and 
apples) 
Direct application of  
5 × 10
7 PFU mL
-1 
phage suspension on 
fruit slices 
Reduction of 
Salmonella 
concentration by 
2.5-3.5 logs on 
melon but not on 
apple  
Matsuzaki 
et al., 2003 
[151] 
Bacteriophage 
fMR11 
Staphylococcus 
aureus 
BALB/c mice  Intraperitoneal 
inoculation with phage 
suspension 
Higher survival 
rate and bacterial 
eradication in 1 and 
7 days 
Nakai and 
Park, 2002 
[12] 
 
Siphoviridae 
isolated from 
diseased fish and 
sea water in fish 
culture cages. 
Lactococcus 
garvieae, 
formerly 
Enterococcus 
seriolicida 
Yellowtail 
Seliora 
quinqueradiata 
and Ayu 
Plecoglossus 
altivelis 
Oral administration of 
phage-impregnated 
feed or intraperitoneal 
injection 
Protective/curative 
effect (increase in 
the survival rate) 
Nakai et 
al., 1999 
[15] 
Siphoviridae 
isolated from 
diseased fish and 
sea water in fish 
culture cages. 
Lactococcus 
garvieae, 
formerly 
Enterococcus 
seriolicida 
Yellowtail 
Seliora 
quinqueradiata 
Oral administration of 
phage-impregnated 
feed or intraperitoneal 
injection 
Protective/curative 
effect (increase in 
the survival rate) 
Park and 
Nakai, 
2003 
[174] 
PPp-W4 
(Podoviridae) 
PPpW-3 
(Myoviridae) 
Pseudomonas 
plecoglossicida 
Ayu 
Plecoglossus 
altivelis 
Oral administration of 
phage-impregnated 
feed (10
7 PFU/fish). 
Reduced infection 
and increased fish 
survival 
Park et al., 
2000 
[27] 
Myoviridae and 
Podoviridae 
isolated from 
diseased ayu and 
the rearing pond 
water 
Pseudomonas 
plecoglossicida 
Ayu 
Plecoglossus 
altivelis 
Oral administration of 
phage-impregnated 
feed 
Protection against 
experimental 
infection 
Toro et al., 
2005 
[158] 
Salmonella – 
specific 
bacteriophages  
Salmonella 
typhimurium 
Chicken   Oral administration  Reduction in 
Salmonella counts 
in cecum and ileum 
treated chickens 
Verner-
Jeffreys et 
al., 2007 
[176] 
 
Aeromonas 
salmonicida phages 
O, R and B 
Aeromonas 
salmonicida 
subsp. 
salmonicida 
Atlantic salmon 
Salmo salar  
Injection  
(1.9 × 10
8 PFU/fish), 
oral administration  
(1.88 × 10
5 PFU g
-1) 
and bath (1.04 × 10
5 
PFU mL
-1)  
Lower rate 
mortality but 
similar absolute 
mortality. No 
protection was 
offered by any of 
the bacteriophage 
treatments. 
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Vinod et 
al., 2006 
[129] 
Siphoviridae  Vibrio harveyi  Shrimp larvae 
Penaeus 
monodon  
In vitro 
ammendment with 
bacteriophage 
suspension  
(10
9 PFU mL
-1) 
Improved larval 
survival 
Watanabe 
et al., 2007 
[150] 
Phage strain KPP10 
isolated from a highly 
polluted river using P. 
aeruginosa strain 
PA20 as the host. 
Pseudomonas 
aeruginosa strain 
D4 (agent of gut-
derived sepsis) 
ICR mice  Intraperitoneal 
inoculation with 
10
10 PFU  
Higher survival rate 
and reduced 
inflammatory 
response after 24 
hours 
Wills et 
al., 2005 
[152] 
Bacteriophage LS2a  Staphylococcus 
aureus strain 2698 
(abscess forming) 
New Zealand 
White rabbits 
Subcutaneous 
injection with  
2 × 10
9 PFU  
Prevention of 
abscess formation 
 
Nakai et al described the in vivo survival of L. garvieae bacteriophages and the potential of the 
phage for controlling experimental L. garvieae infection in yellowtail [15]. Phages were administered 
by injecting phage infected cells into spleen or intestine, to avoid fish defense, and also by phage-
impregnated food. The survival rate was much higher in yellowtail that were injected with phages after 
challenge with L. garvieae (survival rate 100% of 20 yellowtail), compared with that of control fish 
without phage injection (survival rate 10% of 20 yellowtail). Simultaneous administration of live   
L. garvieae and phage enhanced the recovery of the phage from the fish organs. Protection was also 
obtained in yellowtail receiving phage-impregnated feed. Orally administered phage was detected at 
high plaque-forming units from the intestines and spleens of the phage-treated fish until 48 hours after 
administration. These results indicate that intraperitoneally or orally administered anti-L. garviea e 
phage prevented fish from experimental L. garvi eae infection, suggesting the potential use of the 
phage for controlling the disease and that the use of bacterial cells as a protector or vehicle did not 
influence the curative effect of phage. Neutralizing antibodies were not detected in the fish sera that 
repeatedly received phages [15]. Following, two types of bacteriophages specific to P. plecoglossicida, 
the causative agent of bacterial hemorrhagic ascites disease in cultured ayu fish were isolated from 
diseased ayu and from rearing pond water [27]. Oral administration of phage-impregnated feed to ayu 
resulted in protection against experimental infection with P. plecoglossicida. After oral administration 
of P. plecoglossicida, cells of this bacterium were always detected in the kidneys of control fish that 
did not receive the phage treatment, while the cells quickly disappeared from the phage-treated fish. 
Ayu mortality was significantly lower in phage-treated fish (22.5% of mortality) than in the non-
infected fish (60% of mortality). These results indicate that orally administered phage can be expected 
to kill bacterial cells in internal organs, as well as bacterial cells in the intestine, which means that 
phage therapy can be effective at the systemic infection stage. All phage isolates obtained in this study 
were P. plecoglossicida specific but not strain specific, suggesting that a single phage strain or a few 
phage strains could provide effective phage therapy. The fact that infection was established by oral 
route also suggests that the intestine is an important portal of entry for the pathogen, and the narrow 
host range of phage should be an advantage in phage treatment because the phage does not harm the Mar. Drugs 2009, 7                         
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normal intestinal microflora. Phage-resistant variants of P. plecoglossicida, which were induced in 
vitro, lacked virulence for ayu, and no phage-resistant variants were obtained from fish that died after 
phage treatment, suggesting that phage could be used to control this disease. The therapeutic effects 
against  P. plecoglossicida  infection in ayu, using the two previously isolated phages were also 
examined [174]. The mixture of the two phages exhibited the highest inhibitory activity. Mortalities of 
fish receiving one of the phage varied from 53.3 to 40.0%, decreasing to 20.0% when the mixture of 
the two phages were used, but increasing to 93.3% in the control fish receiving no phages. Their 
results showed the therapeutic effect of phages in natural infections. In a field trial, when phage-
impregnated feed was administered to ayu in a pond where the disease occurred naturally (fish 
mortality about 10 Kg d
-1 (ca. n = 900 d
-1), daily mortality of fish decreased at a constant level (5 % 
per day) from days 3 to 15, reaching a steady state at about 6 Kg mortality d
-1 (ca. n = 300 d
-1) 
thereafter, corresponding to one-third reduction in relation to natural conditions. They confirm the 
success of phage treatment by detecting neither phage-resistant organisms nor phage-neutralizing 
antibodies in diseased fish or apparently healthy fish, respectively. 
More recently, other studies on phage therapy have been carried out to control bacterial infections 
in fish farms. Imbeault et al. confirmed the earlier results of Park and Nakai [174], showing that 
bacteriophage combination could be successfully used in preventive programs on fish farms [175]. 
They studied the interaction between A. salmonicida and a bacteriophage to treat furunculosis in brook 
trout. Their results showed that more than one phage could infect A. salmonicida and that mutant 
resistant to one phage was sensitive to other or more phages. Resistant bacteria had a shorter 
generation time than the original strain and the success of their replating was very low. More than 25% 
of the mutants seemed to revert to the original strain phenotype after the first plating. All mutants were 
sensitive to three or more phages [175]. In another recent study, phage therapy was also used to control 
furunculosis of Atlantic salmon caused by A. salmonicida [176]. Fishes which were injected with 
bacteriophages immediately after challenge, died at a significant slower rate than those that were either 
not treated with phages or treated 24 hours past challenge. However, the end result (100% mortality) 
was not affected. Phages were isolated from fish that had succumbed to furunculosis but phages-
resistant A. salmonicida isolates were recovered from mortalities in all the treatments. The results 
show that although there were no safety problems associated with the approach, furunculosis in 
Atlantic salmon is not really controllable by phages application. Walakira et al. isolated to two lytic 
bacteriophages specific for Edwardsiella ictaluri that cause enteric septicemia of catfish [177]. Each E. 
ictaluri strain tested was susceptible to phage infection with variable efficiencies but with no evidence 
of lysogeny and with no plaques detected on other bacterial species, demonstrating their potential use 
as biotherapeutic and diagnostic agents associated with enteric septicemia of catfish. A number of lytic 
phages of Flavobacterium psychrophilum that infect trout, causing the rainbow trout fry syndrome 
disease and cold water disease in fish farms were also isolated [178] and these phages showed broad 
host range on F. psychrophilum, suggesting that they could be used in phage therapy. 
Some other studies focused in diseases caused by luminescent vibrios such as Vibrio harveyi and 
closed related bacteria as for instance Vibrio campbelli, V. parahaemolyticus, Vibrio cholerae and  
V. vulnificus that infect hatchery environments have only recently been reported (Table 1). Some of 
these bacteria also infect fish farm plants and cause serious human infections. A host range of seven Mar. Drugs 2009, 7                         
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phages from hatchery and creek water of aquaculture systems specific to V. harveyi were characterized 
and showed that all the phages were highly lytic against V. harveyi, showing different lytic spectrum 
for the large number of isolates tested (183 isolates) [128]. These phages lysed between 15 and 65% of 
the strains. Six of the seven phages have a broad lytic spectrum and could be potential candidates for 
biocontrol of the V. harveyi in aquatic systems. None of the phages were able to infect other Vibrio 
species. In another study a phage with lytic activity against all fifty V. harveyi tested were isolated 
from shrimp farm water [129]. This phage was tested both in laboratory system and in a hatchery for 
its potential to protected Panaeus monodon  from luminous vibriosis. Microcosm studies with   
P. monodon larvae infected with V. harveyi showed that larval survival in the presence of phages was 
enhanced (80%) as compared with the control (25%). Treatment with bacteriophages improved larval 
survival and brought about decline in luminescent V. harveyi counts in hatchery tanks. Interestingly, 
the phages treatment performed much better than daily addition of antibiotics (5 mg L
-1 oxytetracyclin 
and 10 mg L
-1 kanamycin). The results showed that antibiotic treatment led to initial reduction of 
luminous bacteria after forty-eight hours when bacteria proliferate to about 10
6 PFU mL
-1 (survival of 
40%) but when the water was treated with phages the luminous bacteria were not detected throughout 
the seventeen day study period (survival of 86% in the phage treated tank). The phages used in this 
study did not carried virulence genes. The results suggest that bacteriophages have potential for 
biocontrol of V. harveyi in hatchery systems [129]. Karunasagar et al. also isolated four lytic phages 
from oyster tissue and from shrimp hatchery water that lysed 55-70% of the one hundred V. harveyi 
isolates tested [130]. The bacteriophage treatment at 2 × 10
6 PFU mL
-1 level resulted in over 85% 
survival of P. monodon larvae. Bacteriophages used in this study are not associated with virulence of 
V. harveyi  but are effective in controlling the population of these bacteria in hatchery systems. 
However, Chrisolite et al . showed that although phages of the luminescent V. harveyi  occur in a 
hatchery and co-exist with V. harveyi cells, the outbreak of luminescent bacterial disease in the shrimp 
system remained [179]. 
 
2.4. Advantages of Phage Therapy over Chemotherapy in the Environment 
 
There are several potential advantages of the application of phage therapy over chemotherapy in the 
environment. (1) Specific target, phages are usually highly specific to a single species or even strain of 
bacteria and therefore cause much less damage to the normal intestinal fish flora and to natural non-
target bacteria. (2) Limited resistance development, bacteria will certainly develop resistance to phages 
too, but since phages have a higher mutation and replication rate, they can outcompete the adaptation 
of the bacteria and development of resistance is therefore limited. Moreover, it is comparably easier to 
find new phages than new antibiotics because phage co-evolving with their host bacteria, 
outnumbering bacteria in the environment by tenfold, makes possible the rapid isolation of new lytic 
phages from the environment for phage-resistant bacterial mutants. So, even if the bacteria acquire 
phage resistance, new mutant phage that acts lytically against these bacteria can be used against the 
targeted bacteria [151]. Smith et al. showed that infections produced by phage-resistant mutants of an 
enteropathogenic strain of E. coli and their parents could be successfully controlled with mutant phage 
derived from phage that had been active against the parent bacteria [180,181]. It is already possible to Mar. Drugs 2009, 7                         
 
 
284
prepare a mixture of different strains of phages that would prevent the emergence of a resistant strain 
during phage treatment. On the other hand, purified phage-encoded peptidoglycan hydrolase (lysin) 
has been reported to be effective for the treatment of bacterial infectious diseases caused by Gram-
positive bacteria such as Streptococcus pyogenes, S. pneumoniae, Bacillus anthracis and group B 
streptococci. Therefore, the solution to the problem of phage-resistant bacteria can be found.   
(3) Limited impact, unlike antibiotics, phages are self-replicating as well as self-limiting. They 
replicate exponentially as bacteria and decline when bacteria number decreases. Depending of the form 
of application, a single dose may be sufficient. Reports have revealed that a single treatment with 
phage leads to recovery in mice with infections caused by E. coli  [182], P. aeruginosa  [149], 
methicillin-resistant S. aureus [151], and vancomycin-resistant E. faecium [150,153]. (4) Regulatory 
approval, since phages are naturally occurring and very abundant, there may be substantially fewer 
problems involved in obtained regulatory approval for their use. (5) High resistance of phages to 
environmental conditions, phages are found within the same environment as their bacterial hosts, 
indicating the ability of these phages to survive in the same surrounding as their host bacteria. It is well 
known that phages are more resistant to environmental conditions that bacteria [183,184]. (6) Flexible, 
fast and inexpensive technology. The use of phages to control infections in aquatic environment as fish 
diseases seems to be particularly promising. As the host fish organisms live in aqueous media, the 
therapeutic phage can have continuous and closely physiological contact with the pathogens in a 
natural arrangement.  
In line with the advantages stated above the use of bacteriophage therapy in aquaculture seems to be 
very promising. However, there is the undesirable possibility that phage particles may be removed 
from the circulatory system by host defence systems, perhaps by neutralization of the administered 
phages by antibodies. The preparation of several phage strains with different antigenicities may solve 
this problem. Duckworth and Gulig have suggested that phage therapy is usually completed before 
specific immunity develops [185]. Furthermore, Merril et al. developed a technique of serial passage 
in mice to select for phage mutants able to remain in the circulatory system, and they isolated phage 
mutants that circulated for long periods [186]. A second important problem is that lytic phages, as 
temperate ones [187-189] may act as vectors for transferring genes to the bacteria, namely genes that 
confer resistance to antibiotics and that encode virulence, transforming even non-pathogenic bacteria 
in pathogenic ones [173,190,191]. The global rate of phage-mediated genetic modification in bacteria 
has been estimated as being up to 20 × 10
15 gene transfer events per second [192] However, it is well 
known that bacterial cell surface act as a virulence factor, but some of the surface components can also 
be the receptor for phage attachment, and consequently phage-resistant variants of a virulent organism 
would not be pathogenic. As stated by Anonymous (1983), adaptation of a pathogen and a phage in 
which the bacterial surface virulence determinant is the attachment site for the phage may be essential 
for successful phage therapy [193]. Consequently, before using phages for therapy it would be 
important to test whether they carry any virulence genes and whether it would be safe to use them. 
 
3. Photodynamic Therapy: A New Antimicrobial Approach to Infectious Disease 
 
The use of light to treat a disease is referred to as phototherapy [194,195] and its use goes back to 
the ancient civilizations where heliotherapy was used to improve certain disease conditions, and Mar. Drugs 2009, 7                         
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extracts of plants and seeds were used to enhance pigmentation induced by sunlight. Nowadays, 
phototherapy constitutes a branch of medicine and has its major applications in dermatological 
diseases, neonatal jaundice and more recently in the treatment of bladder, esophageal, gastric, cervical 
and lung cancers and some other diseases [196-198]. The term photodynamic action (photodynamische 
Wirkung) was introduced in 1903 by Hermann von Tappeiner based on Raab studies. These studies 
showed that the combined action of light and a drug (acridine orange) killed paramecia efficiently. 
Indeed the main characteristic of photochemotherapy is the fact that either factor alone is ineffective 
and only their concurrent action makes them therapeutically successful [199]. The photodynamic 
process comprises the action of three components: a photosensitizing agent, visible light and the 
presence of oxygen. The concept of photochemotherapy is based on the preferential affinity of the PS 
to target cells. The subsequent irradiation with visible light in the presence of oxygen induces cell 
damage extensive enough to ensure the inactivation of the microorganisms. It is generally accepted 
that cytotoxic agents such as singlet oxygen (
1O2) and reactive oxygen radicals (hydrogen   
peroxide [H2O2], superoxide [O2
•-], hydroxyl radical [-OH
•-]) generated by the PS action which transfer 
part of the absorbed energy to molecular oxygen, are the species causing cell disruption [196,200-204]. 
 
3.1. Photosensitizers 
 
A photosensitizer (PS) can be a natural or a synthetic compound which undergoes excitation after 
interaction with an appropriate radiation emitted from a light source. This gives rise to activated 
species (e.g., molecular oxygen) which are very reactive towards the chemical environment thus 
producing molecular consequences on important biological targets. For a compound to be considered 
for use in photodynamic treatment it must fulfill some properties which are application dependent. 
However, regardless of other requisites, all of the PS must have good absorption capacity at the 
wavelength of the spectral region where the light is emitted and show good efficiency to generate 
singlet oxygen [205-207]. The photosensitizing properties of organic dyes (such as rose bengal, eosin, 
and methylene blue), fullerenes [208], porphyrins (of natural and synthetic origin), phthalocyanines 
and related tetrapyrrolic macrocycles, were evaluated (Figure 1).  
 
Figure 1. Skeletons of xanthene (I), phenothiazine (II), porphyrin (III) phthalocyanine (IV) 
and fullerene (V) photosensitizers. 
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In photodynamic treatment of cancer, three generations of PS can be identified. The first generation 
comprises the Haematoporphyrin derivative (HpD) and its analogues including Photofrin
®, the first 
formulation approved for cancer treatment in several countries; second generation is constituted by 
structurally distinct compounds with long-wavelength absorption; and the third generation comprises 
the above mentioned structurally distinct compounds with long-wavelength absorption, but now bound 
to carriers for selective accumulation in the tumors (e.g., antibodies) [205]. 
Porphyrins and analogues have been the most promising compounds used in photochemotherapy. 
Their natural occurrence and the important role in vital processes such as photosynthesis, oxygen 
transport and storage were responsible for decades of research devoted to the establishment of new and 
efficient synthetic methodologies to prepare them. New and highly efficient synthetic routes have 
generated many porphyrin-like compounds with unique characteristics for their uses in several other 
applications such as oxidative catalysis [209,210] and as biomimetic model systems of the primary 
processes of photosynthesis [211,212]. Presently, the interest also includes the supramolecular units, 
namely molecular recognition in chemical receptors and sensors [213-215], as light-harvesting   
devices [216-219] and as materials for advanced technologies, mainly in nanosciences [220,221]. 
Nevertheless, the photodynamic treatment is certainly the most promising application of porphyrin-like 
compounds. 
The photodynamic treatment efficiency, namely in the photoinactivation of microorganisms, 
depends on several factors such as the presence or absence of charge, charge distribution and the 
presence of peripheral substituents. The porphyrin skeleton is essentially hydrophobic. This feature 
may be an important factor affecting the preferential accumulation in cellular hydrophobic loci since 
such molecules must be able to get into cells by crossing lipid membranes which brings insolubility in 
water and physiological fluids. To overcome this fact, adequate formulations have to be   
used [222-224]. However, the structural modification of the porphyrinic core can provide the required 
peripheral substituents (like the carbohydrate residues, charge groups with positive charge) used to 
control water solubility and their affinity for target cells [225,226]. For instance, synthetic porphyrins 
may be transformed into cationic entities through the insertion of positively charged substituents in the 
peripheral positions of the macrocycle which may largely affect the kinetics and extent of binding with 
microbial cells [44,100,103]. The charge on a photosensitizing molecule plays an important role in its 
biological properties. Cationic meso-substituted porphyrins have been proved to be more efficient and 
more photostable in water disinfection than other cationic PS as methylene blue (phenothiazinium dye) 
and rose bengal (xanthene dye) [227]. 
The nature and distribution of some functional groups in the molecule make it hydrophobic, 
hydrophilic or amphiphilic. Information about these properties is important because they affect, in a 
crucial way, the photophysical parameters and the efficacy of the PS [228]. A chemical compound is 
amphiphilic if possesses both hydrophilic and hydrophobic characteristics. In the transport system of 
cell membranes, the lipid bilayer of the membrane allows for passive transport of hydrophobic 
molecules. This means that molecules that repel water may diffuse across the cellular membrane 
without the need for an active transport system, like that of adenosine 5'-triphosphate. Therefore, the 
hydrophobic PS can more easily diffuse across the cell membrane and improve the efficiency of 
photodynamic effect. But as mentioned, the PS must be in solution, so it needs to be hydrophilic. Mar. Drugs 2009, 7                         
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Therefore, the ideal PS must have both hydrophilic and hydrophobic properties, making it amphiphilic. 
There are some factors which increase the amphiphilic character of the porphyrins such as the 
asymmetric charge distribution at their peripheral positions, and charges combined in different patterns 
with highly lipophilic groups (e.g., trifluoromethyl groups) [229-235]. The increase in the amphiphilic 
character of the PS seems to enhance its affinity for microorganisms which helps a better accumulation 
in the cells/particles [231,235,236] accompanied by an increase in the photocytotoxic activity [233]. 
Besides lipophilicity properties, other important parameters in the make-up of the PS must be 
considered. The degree of ionization, electric charge, molecular size, non-specific protein binding are 
same of the other factors which influence the photodynamic therapy response [237]. 
 
3.2. Photodymamic Therapy and Its Clinic Applications  
 
At the beginning of its history, the first photochemotherapeutic approach was applied in medicine in 
1903 by Albert Jesionek and Hermann von Tappeiner to the treatment of patients with malignant skin 
lesions [238]. However, since the middle of the last century, photochemotherapy applied to 
microorganisms was forgotten mainly because of the discovery and massive production of   
antibiotics [202]. Nowadays, photochemotherapy applications are again found in medicine, namely in 
the treatment of tumours. Photodynamic therapy (PDT) is the name commonly given to 
photochemotherapy of cancer [200]. In PDT, the administered photosensitizing compound selectively 
accumulates in the target cells and local irradiation is employed on the lesion (visible light, normally 
laser light delivered by optical fibers) [201,239,240]. The combination of two nontoxic elements, i.e. 
drug and light in the presence of molecular oxygen in the surrounding medium results in the selective 
destruction of tissue [239] through very localized cytotoxic effect [201]. 
Since the 1990’s, PDT has been successfully employed in the treatment of many tumors, including 
skin cancer, oral cavity cancer, bronchial cancer, esophageal cancer, bladder cancer, head and neck 
tumors in addition to nonmalignant diseases [241]. Besides cancer treatment, a very successful PDT 
application (FDA approved) has been in ophthalmology, to treat age-related macular   
degeneration [242]. 
Although the main use of PDT has focused on cancer treatment, the worldwide emergence of 
antibiotic resistance amongst pathogenic bacteria has led to a major research effort to find alternative 
antibacterial therapeutics [243] to which, it is hypothesized, microorganisms will not easily be able to 
develop resistance.  
Currently, photodynamic antimicrobial chemotherapy (PACT) is receiving considerable attention 
for its potentialities as a new form of antimicrobial treatment [44,203,206]. All studies that have 
examined the killing of antibiotic resistant bacteria by the combination of PS and light, have found 
them to be equally as susceptible as their native counterparts [203,204,244]. Studies carried out with 
porphyrin derivatives pointed out to the great potentialities of this type of compounds for biomedical 
applications [196,228]. Recent studies, in particular, have demonstrated that PACT can be effective in 
the selective inactivation of microorganisms and it can become a potential alternative for the treatment 
and eradication of microbial infections [202,245]. Because the delivery of visible light is almost by 
definition a localized process, PACT for infections is likely to be applied exclusively to localized Mar. Drugs 2009, 7                         
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disease, as opposed to systemic infections, such as bacteremia [202]. In contrast to PDT for cancer, 
where the PS is usually injected into the bloodstream and accumulates preferentially in the tumor cells, 
PACT for localized infections is thought to be carried out by local delivery of the PS into the infected 
area by several methods such as topical application, instillation, interstitial injection or aerosol   
delivery [202]. The key issues that need to be addressed considering the photoinactivation of 
microorganisms are the effectiveness of the treatment in destroying sufficient numbers of the disease-
causing pathogens; effective selectivity of the PS for the microbes, thus avoiding an unacceptable 
degree of photodynamic damage to host tissue in the area of infection; and the avoidance of regrowth 
of the pathogens from a few survivors following the treatment [202]. One of the main applications of 
PACT in the clinical area consists in the sterilization of blood and blood products, preventing of viral 
contamination. Remarkably, the human immunodeficiency virus has been inactivated in v itro by 
PACT [207,246-250]. Further applications of PACT would be skin surface disinfection, decolonization 
of nasal MRSA and wound healing in the future [44,202,237,251]  
 
3.3. Photodymamic Antimicrobial Therapy Application in the Environment 
 
Currently, photodynamic antimicrobial therapy has been studied having in view not only its 
application to the clinical field, but also to the environmental area [204,227,232,233,235,236,244, 
252-269] (Table 2). This approach has been considered as a possibility for use in water   
disinfection [227,270]. Traditional water disinfection methods use chlorine, chlorine dioxide, ozone 
and ultraviolet radiation and are very efficient against a large range of microorganisms [271]. 
However, those treatments involve high costs and difficulties of implementation at large scale due to 
operational, personnel qualification and logistic deficits [271]. Ultraviolet radiation and ozone 
treatment are very expensive options to apply to a larger scale and disinfectants form toxic by-
products, being the chlorine’s by-products the most toxic ones [272]. Effectiveness of PACT was 
observed on the destruction of faecal bacteria [227,253,273-277], viruses [278,279] and helminths 
eggs [280] in environmental waters.  
The extension of the photodynamic principle to a new environmentally-friendly technology can 
become economically viable if the PS is immobilized on a solid matrix in order to allow the 
photoinactivation process and subsequent retention of the PS, after photodynamic action, to avoid the 
release of the PS to the water output [277,281]. As a consequence, some studies have developed PS 
immobilized on solid supports and the photodynamic inactivation (PI) against faecal bacteria was 
tested [232,275,277,281,282]. Bonnett et al .  used a phthalocyanine immobilized on a polymeric 
membrane of chitosan in a model reactor of water disinfection [281]. They used an E. coli suspension 
of 10
5 cell mL
-1 representing the significant levels of water contamination. Also, when the dyed 
membrane was stored in the dark for nine months, the photodynamic action was still detectable, 
demonstrating the thermodynamic stability of the PS system. They concluded that with that model 
system, the photoinactivation with immobilized PS can be used to lower microbial levels in water flow 
systems and that might also have applications in water detoxification [281]. The same group also 
immobilized zinc phthalocyanines in a silicate matrix to test their photobactericidal properties on   
E. coli  in model aqueous media. Although they obtained moderate PI, they concluded that Mar. Drugs 2009, 7                         
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phthalocyanines can be immobilized successfully in a silicate matrix and also used for 
photodisinfection of microbially polluted waters [232,275,277,281,282]. Regenerated cellulose 
impregnated with 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin tetra-p-tosylate showed 
photobactericidal activity against S. aureus, E. coli, Proteus vulgaris and Bacillus subtilis [275]. Two 
mono-hydroxyl zinc-porphyrin derivatives were immobilized on poly(methyl methacrylate), with 
respectively anionic and cationic net charge. The cationic derivative immobilized on poly(methyl 
methacrylate) polymer showed to have effective inhibitory effect in the photoinactivation of 
Deinococcus radiodurans [283]. Krouit et al. showed efficient photoinactivation of Gram-positive and 
Gram-negative bacterial strains by cellulose films with immobilized porphyrin derivatives [284-286]. 
Presently, new inorganic-organic hybrids (‘smart’ materials) based on tricationic porphyrin derivatives 
are also used at the photoinactivation of a large spectrum of microorganisms [287]. Preliminary results 
obtained with a tricationic porphyrin derivative immobilized in nanoparticles showed that inorganic-
organic hybrids present antimicrobial activity and allows the recovery and recycling of the 
photosensitizing agent [287-289]. One of the tested inorganic-organic hybrids was able to inactivate 
Gram-positive, Gram-negative and T4-like bacteriophage to the limits of detection (up to 7 logs of 
inactivation) as the PS did in the unbound form [288,289]. Besides, Jiménez-Hernández et al. used as 
sensitizers, Ru(II) polypyridyl complexes grafted to polymer in a homemade microreactor with a solar 
simulator source for laboratory-scale water disinfection assays using a water sample containing E. coli 
and Enterococcus faecalis (2 × 10
3 CFU mL
-1). They concluded that photodisinfection with visible 
light was significant against both microorganisms [277].  
 
Table 2. Use of photosensitizers and light to inactivate pathogenic microorganisms. 
Reference Mi croorganisms  Photosensitizer (PS)  Concentration 
of PS 
Irradiation 
time 
Type of light  Light dose  Fluence 
rate 
Cell 
concentration 
Alouini et 
al., 2001 
[280] 
Helminth eggs  Cationic meso-substituted 
porphyrin, tetra-(4-N-
methylpyridyl) porphin 
tetratosylate (T4MPYP) 
10 µM  30 minutes  Visible light    0.5 W cm
-2 15-20  cell  mL
-1 
Alves et 
al., 2008 
[273] 
Recombinant 
bioluminescent 
Escherichia coli (E. coli) 
Three cationic meso-
substituted porphyrin 
derivatives 
0.5 µM, 1µM 
and 5 µM 
0-270 
minutes 
Artificial 
white 
light/sunlight 
64.8 J cm
-2/ 
1004.4  
J cm
-2 
40 W cm
-2/ 
~620  
W cm
-2 
10
7 CFU mL
-1 
Alves et 
al., 2009 
[274] 
E. coli and Enterococcus 
faecalis (E. faecalis) 
Seven cationic porphyrins 
differing in meso-
substituent groups, charge 
number and charge 
distribution 
0.5 µM, 1 µM 
and 5 µM 
0-270 
minutes 
White light  64.8 J cm
-2 40  W  cm
-2 10
7 CFU mL
-1 
Banfi et al., 
2006 
[230] 
E. coli, Pseudomonas 
aeruginosa and 
Staphylococcus aureus 
(S. aureus) 
Three tetracationic 
porphyrins, a dicationic 
porphyrin and a neutral 
porphyrin 
0.4-60 µM  30-60 
minutes 
Visible light  266 J cm 
-2   10
8 CFU mL
-1 
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Caminos 
and 
Durantini, 
2006 
[232] 
E. coli immobilized 
on agar surfaces 
5,10,15-tris[4-(3-N,N,N-
trimethylammoniumpropoxy)p
henyl]-20-(4-
trifluoromethylphenyl)-
porphyrin iodide and 
5,10,15,20-tetra(4-N,N,N-
trimethylammoniumphenyl)por
phyrin p-tosylate 
0-14 nmol  0-180 
minutes 
Visible light 
(a projector or 
midday sun) 
 90  mW  cm
-2 small 
colonies 
on agar 
surfaces 
Carre et al., 
1999 
[252] 
Saccharomyces 
cerevisiae 
Neutral meso-
arylglycosylporphyrins 
10
-5 M  10-120 
minutes 
Visible light 
(150 W 
tungsten 
lamps) 
  500 W m
-2 10
7 CFU 
mL
-1 
Carvalho et 
al., 2007 
[253] 
Faecal coliforms  Two sets of neutral and 
cationic porphyrins 
5 µM  270 minutes  White light (9 
mW cm
-2) 
    
Cormick et 
al., 2009 
[254] 
Candida albicans (C. 
albicans)strain PC31 
5-(4-trifluorophenyl)-10,15,20-
tris(4-trimethyl-
ammoniumphenyl) 
porphyrin iodide (TFAP
3+); 
5,10,15,20-tetra(4-N,N,N-
trimethylammonium-
phenyl)porphyrin p-tosylate 
(TMAP
4+); 5,10,15,20-tetra(4-
sulphonatophenyl) 
porphyrin (TPPS4 ) sodium 
salt 
1 µM-5 µM  240 minutes  Visible light 
(350-800 nm) 
 90  mW  cm
-2 10
6-10
8  
CFU mL
-1 
Demidova 
and 
Hamblin, 
2005 
[255] 
E. coli ,S. aureus, C. 
albicans 
Rose bengal, toluidine blue O, 
and a poly-L-lysine chlorin(e6) 
conjugate  
(pL-ce6) 
2-3.3 mM    Visible light 
(noncoherent 
light source 
with 
interchangeab
le fiber 
bundles) 
0 to 200  
J cm
-2 
50 to 400 
mW cm
-2 
10
7-10
8  
CFU mL
-1 
Demidova 
and 
Hamblin, 
2005 
[256] 
Bacillus atrophaeus 
(ATCC 9372), B. 
cereus 
(ATCC14579), B. 
megaterium 
(ATCC14581), B. 
thuringiensis (ATCC 
33740) and B. 
subtilis (ATCC 
6051) 
Rose bengal, toluidine blue O, 
methylene blue, new 
methylene blue N (zinc 
chloride double salt; NMBN), 
1,9-dimethylmethylene blue 
chloride (DMMB), 5-phenyl-
10,15,20-tris(N-methyl-4-
pyridyl-)porphyrin chloride 
[TriP(4)], poly-L-lysine 
chlorin(e6) conjugate, 
benzoporphyrin 
derivative 
5µM-1.600 µM  180 minutes  Visible light 
(noncoherent 
light source 
with 
interchangeab
le fiber 
bundles) 
0 to 200  
J cm
-2 
200 to 400  
mW cm
-2 
10
7  
CFU mL
-1 Mar. Drugs 2009, 7                         
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Drábková 
et al., 2007 
[257] 
Cyanobacteria Phthalocyanines,  tetraphenol 
porphyrine, methylene blue 
0.001-5  
mg L
-1 
60 minutes  White ligh 
(5000 lx 
under 
fluorescent 
tubes) 
 5000  lx 
under 
fluorescent 
tubes 
10
5-10
6 
CFU 
mL
-1 
Ehrenberg 
et al., 1993 
[258] 
S. aureus and E. coli  Mg and Zn-tetrabenzoporphyrin             
Foschi et 
al., 2007 
[259] 
E. faecalis (ATCC 
29212) 
Methylene blue  16.75 mM  10 minutes  Diode laser  60  
J cm
-2 
100 mW 
cm
-2 
10
9 CFU 
mL
-1 
Gábor et 
al., 2001 
[260] 
E. coli and 
Enterococcus hirae 
Exogenous and endogenous 
porphyrin derivatives 
1.2 × 10
-6- 
4 × 10
-3 M 
120 minutes  White ligh 
(halogen 
lamp) 
 0.08-0.25   
W cm
-2 
10
7 CFU 
mL
-1 
Grinholc et 
al., 2008 
[261] 
40 methicillin-
resistant S. aureus 
(MRSA) and 40 
methicillin sensitive 
S. aureus (MSSA) 
strains; and also one 
reference 
strain of S. aureus 
(ATCC 25904) 
Protoporphyrin diarginate 
(PPArg2) 
25 µM    White ligh 
(624 nm) 
12  
J cm
-2 
  
Jemli et al., 
2002 
[227] 
Fecal coliforms  Rose Bengal, methylene blue, 
meso-substituted cationic 
porphyrin 
1µM, 5µM, 
10µM 
60 minutes  Sunlight  234 µM  
m
-2 s
-1 
1235 mW 
cm
-2 
 
Lazzeri et 
al., 2004 
[236] 
E. coli  Asymmetric meso-substituted 
cationic porphyrins: 5,10-di(4-
methylphenyl)-15,20-di(4-
trimethylammoniumphenyl)porph
yrin iodide 1 and 5-(4-
trifluorophenyl)-10,15,20-tris(4-
trimethylammoniumphenyl)porph
yrin iodide 2 and its metal 
complex with Pd(II) 3 and a non 
cationic sensitizer 5-(4-
carboxyphenyl)-10,15,20-tris(4-
methylphenyl)porphyrin 4 
10 µM  30 minutes  Withe ligh 
(slide 
projector 
equipped with 
a 150 W 
lamp) 
  90 mW  
cm
-2 
10
6 CFU 
mL
-1 
Maisch et 
al., 2005 
[262] 
Two MRSA strains, 
one MSSA strain, 
one methicillin-
resistant 
Staphylococcus 
epidermidis strain, 
one E. coli strain 
Porphyrin-based photosensitizers 
(CTP1, XF70, and XF73) 
0-10 µM  15 minutes  Visible light 
(incoherent 
light source, 
UV236; 380 
to 480 
nm) 
13.7  
J cm
-2 
15.2 mW 
cm
-2 
10
8-10
9 
CFU 
mL
-1 Mar. Drugs 2009, 7                         
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Merchat et 
al., 1996 
[263] 
Vibrio anguillarum 
E. coli 
Enterococcus 
seriolicida 
Two meso-substituted cationic 
porphyrins: tetra(4N-methyl-
pyridyl)porphine tetraiodide and 
tetra(4N,N,N-trimethyl-
anilinium)porphine, and 
negatively charged meso-
substituted porphyrin, tetra(4-
sulphonatophenyl)porphine 
10 µg mL
-1 0-30 
minutes 
White light 
(four 250 W 
tungsten 
lamps) 
 6  mW  cm
-2 10
8  
CFU mL
-1 
Merchat et 
al. (b), 
1996 
[264] 
Vibrio anguillarum 
E. coli 
Enterococcus 
seriolicida 
meso-tetra (4-N-methyl-
pyridyl)porphine tetraiodide, 
T4(4-N-MePy)P; meso-tetra (3-
N-methyl-pyridyl)porphine 
tetrachloride, 1"4(3-N-MePy) P; 
tri(4-N-methyl-
pyridyl)monophenylporphine 
Iritosylate, T3(4-N-MePy) PhP; 
di(N-methyl-4-
pyridyl)diphenylporphine 
dichloride (D(4-N-MePy) Ph2P 
8.4 µM  0-30 
minutes 
White ligh 
(250 W 
quartz-
tungsten 
lamps) 
 6  mW  cm
-2  
Nitzan and 
Ashkenazi, 
2001 
[266] 
Acinetobacter 
baumannii and 
Escherichia coli B 
Cationic TMPyP  29.4 mmol L
-1 
(p), 3.7 mmol 
L
-1 (}), 1.83 
mmol L
-1 (F), 
and 0.73 
mmol L
-1 (h) 
 Blue,  green 
and red light 
 140-150 
mW cm
-2 
10
9 CFU 
mL
-1 
Nitzan et 
al., 1998 
[269] 
Acinetobacter 
baumannii 
Deuteroporphyrin (Dp) and 
polymyxin nonapeptide (PMNP) ; 
Cd-texaphyrin (Cd-Tx) in the 
presence of PMNP; cationic 
photosensitizer tetra-
methylpyridyl porphine 
(TMPyP); anionic photosensitizer 
tetra-sulfonatophenyl porphine 
(TPPS4) 
Deuteroporph
yrin (Dp) at a 
concentration 
of 34 Ixmoles 
I ~ and 
polymyxin 
nonapeptide 
(PMNP) at a 
concentration 
of 200 
txmoles 1 ~ 
0-210 
minutes 
White ligh 
(unfiltered 
tungsten 
lamps) 
  140 W m
-2 10
8 CFU 
mL
-1 
Oliveira et 
al., 2009 
[267] 
Bacillus cereus 
endospores and 
vegetative cells 
Neutral and cationic porphyrin 
derivatives, and phenothiazinium 
dye toluidine blue O and 
10,15,20-tris(1-
methylpyridinium-4-yl)-5-
(phenyl)porphyrin tri-iodide (Tri-
Py+-Me-Ph, tricationic 
10 and 60 µM  4 and 10 
minutes for 
endospores 
and for 15 
minutes for 
vegetative 
cells 
White light 
(400-800 nm) 
152.1  
J cm
-2 
(maximum 
dosis) 
1690 W m
-2 10
6-10
7 
CFU mL
-1 
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Spesia et al., 
2005 
[235] 
E. coli  Meso-substituted cationic porphyrins, 5-[4-
(trimethylammonium)phenyl]-10,15,20-
tris(2,4,6-trimethoxyphenyl)porphyrin 
iodide 1, 5,10-di(4-methylphenyl)-15,20-
di(4-trimethylammoniumphenyl)porphyrin 
iodide 2 and 5-(4-trifluorophenyl)-
10,15,20-tris(4-
trimethylammoniumphenyl)porphyrin 
iodide 3 
10 µM  5 minutes  Visible 
light 
 0.68,  2.60 
and 90 mW 
cm
-2 
10
6 CFU 
mL
-1 
Tang et al., 
2007 
[268] 
S. aureus (ATCC 
25923), E. coli 
(ATCC 25922), a 
clinical isolate of 
MRSA, and a clinical 
isolate of ESBL-
producing E. coli 
Toluidine blue O and poly-l-lysine 
chlorin(e6) conjugate (pL-ce6) 
4-8 µM  30 minutes  Red 
light 
10-30  
J cm
-2 
400 W  10
8 CFU 
mL
-1 
Wainwright 
et al., 1998 
[204] 
MRSA  strains  Phenothiazinium  dyes          
Wilson and 
Yianni, 1995 
[244] 
MRSA strain  Toluidine blue  1.6-12.5 
µg mL
-1 
1 minute  Low 
power 
helium/n
eon laser 
0.5-2.1  
J cm
-2 
35 mW  10
10 CFU 
mL
-1 
 
3.4. Photodynamic Antimicrobial Therapy Application in Fish Farm Plants 
 
Although just a few studies have been conducted in this field (Table 2), preliminary results obtained 
at both laboratory level and pilot station suggest that the photochemical technique, using porphyrin 
derivatives as PS, has a great potential also for the disinfection of fish farming plant waters [100,290]. 
These studies showed that cell cultures of Gram-positive bacteria (e.g., meticillin-resistant S. aureus), 
Gram-negative bacteria (e.g., E. co li), fungal (e.g., C. albicans ) and fungal-like pathogens   
(e.g., Saprolegnia spp.) and parasitic protozoa (e.g., Acanthamoeba palestinensis) showed a 5-6 log 
decrease in the microbial population after 10 minutes of irradiation with low light intensities   
(ca. 50 mW cm
-2) in the presence of micromolar PS doses [290]. Magaraggia et al. have also shown 
that a micromolar concentration of a porphyrinic PS promoted the cure of saprolegniosis in trout-
farming pools containing naturally or artificially Saprolegnia infected fish (inactivation of 6-7 logs) 
without perilesional damage of the fish. A stock of fish were transferred to a 1,000 L tank and, after 
acclimatization, skin fish was infected by scraping dorsal trout epidermis and inoculated with 
Saprolegnia by direct contact of the lesions with mycelium wads. The infected group was dark 
incubated with 0.6 mg L
-1 for 10 min in an 80-150 L pool and irradiated for 1 h kept in a closed circuit 
and recirculated by a motor-driven pump. The irradiation was performed by using the 400-800 nm 
wavelength interval emitted from two 100 W incandescent filament lamps and the water temperature 
was kept at 13 °C throughout the light exposure. The treatment was daily repeated for six consecutive Mar. Drugs 2009, 7                         
 
 
294
days. After each treatment repetition, fish were moved to a 1,000 L tank. The onset of the infection in 
healthy fish was reduced about 50%. Recurrence of the saprolegniosis in the Saprolegnia infected sites 
or in others sites of the fish was not observed. The trout set with spontaneous infection by Saprolegnia 
a complete remission of the infection was induced within one week. The same micromolar 
concentrations exhibited also higher photosensitizing activity over meticillin-resistant S. aureus and  
E. coli  (up 7 logs decrease) [100]. The antimicrobial effects of PDT were also demonstrated for   
V. v ulnificus that frequently infects fish farming water [291]. Similarly, ten bacterial species   
(V. anguilarum, V. parahaemol yticus,  Photobacterium damselae  subsp. damselae,  Photobacterium 
damselae subsp. piscicida,  A. salmonicida ,  E. coli ,  Enterobacter,  S. aureus ,  E. fae calis,  
Pseudomonas sp.) isolated from a fish farming plant waters were effectively inactivated (up to 7 logs) 
in vitro with cationic porphyrins, at micromolar PS doses, after 90-270 minutes of irradiation with a 
very low light intensity of 4 mW cm
-2 [292], showing that photodynamic therapy can be used to 
photoinactivate fish bacterial pathogens in fish farm waters even during dark days of winter time. In 
these experiments fifty milliliters of bacterial suspensions from bacterial cultures (~10
8 cells mL
-1) 
were diluted ten-fold in phosphate buffered saline to a final concentration of ~ 10
7 colony forming 
units mL
-1 and exposed, in 600 mL glass beakers, to the PS under the white light. Bacterial inactivation 
was evaluated by counting the number of colonies, by pour plating method, in the exposed samples. 
Irradiation of fish farming waters by solar light, which penetrates deeply into the water column, 
thereby allowing the uniform illumination of large volumes [293] makes this technology inexpensive 
since it is based on the use of low cost visible light sources. 
The promising results of PACT on a large range of microorganisms, Gram-positive and Gram-
negative bacteria including multidrug-resistant strains, bacterial spores, virus, bacteriophages, yeasts 
and helminths eggs [233,243,255,256,267,273,274,276,279,294-299] and the knowledge that the 
porphyrins’ mode of action make the selection of photoresistant strains very unlikely [237,300], 
suggest that this principle can be applied to photodecontamination of fish farming plants, in order to 
destroy pathogenic microorganisms. To implement this technology in fish farming plants some studies 
will be need to be carried out, namely pertaining to the determination of the stability of the new 
hybrid-porphyrin conjugates under visible light irradiation conditions. Moreover, there are no studies 
on the impact that this procedure might have on the total microbial community structure after 
treatment. 
 
3.5. Advantages of Photodynamic  Antimicrobial Che motherapy over other Treatments in the  
Environment 
 
The main favorable aspects of PACT for environmental use are the following [44,251]: (1) a broad 
spectrum of action: the PS inactivates efficiently bacteria, viruses, fungi, and parasites in both the 
dormant and vegetative states contrarily to chemotherapy and phage therapy; (2) an efficient 
phototoxic activity against both wild and antibiotic-resistant microbial strains; (3) the lack of selection 
of photoresistant microbial species; (4) a low mutagenic potential; (5) a high selectivity in the killing 
of pathogens as compared with the main constituents of potential host tissues; (6) a high selectivity in 
space and time: the microsecond short lifetime and high reactivity of singlet oxygen (the main pathway 
of PACT inactivation), restricts the photooxidative damage to the microenvironment of the site where Mar. Drugs 2009, 7                         
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it is generated to about 0.1 µm [194,195]; (7) the lack of generation of potentially dangerous or toxic 
by-products from photoinduced degradation of the photosensitizing agent; (8) cost-effective 
technology, as it is based on the use of visible light sources, as solar irradiation; (9) the possibility to 
reuse the immobilized PS which makes this technology less expensive and avoids its diffusion to the 
environment, preventing any risk of environmental contamination. 
 
Conclusions 
 
The possibility to inactivate fish pathogenic microorganisms with phages and/or immobilized 
photosensitizers is outstanding, being the major advantage the efficient water disinfection degree 
obtained without risk to fishes or to the environment. The safety of the photodynamic therapy 
approach is increased as porphyrin derivatives apparently do not induce the selection of resistant 
microbial strains. Although, in some cases, phage therapy approach can lead to the selection of 
resistant bacteria, its occurrence and impact is not as so frequent and harmful as antibiotics 
chemotherapy.  
The new approaches described in this review are intrinsically low cost compared to the chemical 
compound normally used in aquaculture systems and are conceived to be environmentally-friendly and 
to exhibit a high level of safety for various ecosystems, as well as for humans, animals and plants.  
More studies are needed in order to gather a detailed understanding of phage-bacterium and of 
photosensitizer-microorganisms interactions in aquaculture systems subjected to different 
environmental pressure. A better understanding of phage therapy and of photodynamic therapy as 
adjuvant use of antibiotics and/or other disinfectant in fish farming plants also need to be   
further studied.  
Each of the two techniques has its advantages but also its limitations. The application of phage and 
of photodynamic therapies must be based on a careful evaluation of each case, before replacing 
conventional approaches. Nevertheless, a good biocontrol management strategy might be the use of 
more than one technique in rotation to prevent resistance development. Alternatively, it might be 
valuable to apply both techniques to maximize protection against pathogenic microorganisms. 
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